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ABSTRACT
Background This study assessed the impact of
simultaneous achievement of clinical, functional and
structural efﬁcacy, herein referred to as comprehensive
disease control (CDC), on short-term and long-term
work-related outcomes, health-related quality of life
(HRQoL), pain and fatigue.
Methods Data were pooled from three randomised
trials of adalimumab plus methotrexate for treatment of
early-stage or late-stage rheumatoid arthritis (RA). CDC
was deﬁned as 28-joint Disease Activity Score using C
reactive protein <2.6, Health Assessment Questionnaire
<0.5 and change from baseline in modiﬁed Total Sharp
Score ≤0.5. Changes in scores at weeks 26 and 52 for
work-related outcomes, Short Form 36 (SF-36) physical
(PCS) and mental component scores (MCS), a Visual
Analogue Scale measuring pain (VAS-Pain) and
Functional Assessment of Chronic Illness Therapy-Fatigue
(FACIT-F) were compared between patient groups
deﬁned by achievement of CDC at week 26 using linear
regression with adjustment for baseline scores.
Results Patients with RA who achieved CDC at week
26 (n=200) had signiﬁcantly greater improvements in
VAS-Pain (46.9 vs 26.9; p<0.0001), FACIT-F (13.3 vs
7.5; p<0.0001), SF-36 PCS (19.7 vs 8.9; p<0.0001)
and SF-36 MCS (8.1 vs 5.0; p=0.0004) than those who
did not (n=1267). Results were consistent at week 52
and among methotrexate-naive patients with early RA,
methotrexate-experienced patients with late-stage RA
and patients with inadequate response to methotrexate.
Conclusions Patients with RA who achieved CDC at
week 26 had improved short-term and long-term
HRQoL, pain, fatigue and work-related outcomes
compared with patients who do not. These results
demonstrate that the joint achievement of all CDC
components provides meaningful beneﬁts to patients.
Trial registration numbers DE019: NCT00195702,
PREMIER: NCT00195702, OPTIMA: NCT00195702.
INTRODUCTION
Rheumatoid arthritis (RA) is characterised by pro-
gressive inﬂammation of the joints and leads to
irreversible joint damage that reduces function and
increases disability.1 2 Current treatment options
have shown to reduce inﬂammation, slow or
prevent joint damage and improve patient-related
outcomes. As per the treat-to-target recommenda-
tions, the primary goal in the treatment of RA
should be achieving the control of symptoms, pre-
vention of structural damage, normalisation of
function and social participation.3 In the European
League Against Rheumatism (EULAR) 2013 guide-
lines, achievement of clinical, functional and struc-
tural efﬁcacy is also the basis for treatment
comparison. However, the impact of such achieve-
ment on patient outcomes has not been adequately
and explicitly assessed.
While the achievement of all clinical, functional
and structural efﬁcacy is the ultimate goal for
disease management, in real world practice, remis-
sion has been recommended as a key treatment
target for adjusting therapy to optimise outcomes
accordingly.3 Over the years, remission has been
deﬁned in several ways, but even with the recently
more stringent American College of Rheumatology
(ACR)-EULAR criteria, nearly 23% of the patients
who achieved ACR-EULAR remission did not
achieve the desired radiographic inhibition.4 It is,
therefore, not guaranteed that remission target
achievement alone would ensure functional and
structural goal achievement. While remission could
be the target for adjusting therapy, the goal of
every treatment should be inhibition of structural
damage and normalise function, in addition to
symptom control.
In deﬁning the three elements of the treatment
goal, there has been a greater evolution in the def-
inition of clinical remission relative to what is
deﬁned for normalised function based on Health
Assessment Questionnaire disability index
(HAQ-DI) and for structural non-progression based
on modiﬁed Sharp score. Remission criteria derived
from Disease Activity Score (DAS) and 28-joint
Disease Activity Score (DAS28) have been the dom-
inant treatment target in clinical practice in this
evolution. Recently developed ACR-EULAR remis-
sion is so stringent that it is difﬁcult to be achieved
by most patients especially those with long-standing
disease who actually constitute the majority of
patients in clinical care. Hence, the EULAR 2013
guidelines recommended less stringent measures as
a good alternative target for many patients who
cannot attain stringent forms of remission.5 Given
this, in the current study, we deﬁne clinical remis-
sion based on DAS28. A cut-off point of DAS28
using C reactive protein (DAS28(CRP)) <2.6 is an
acceptable, as well as stringent enough, quantitative
treatment target for the signs and symptoms of RA
inﬂammation.6
Patient-reported outcomes (PROs) provide
important assessments of functioning and well-
being from the patient’s perspective and may
provide additional tangible impact for a patient,
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and thus be more sensitive to the effects of treatment than
physician-assessed measures.7–10 In some cases, work limitations
are important considerations in the treatment of RA given that
the disease affects patients in their productive years.11 12 RA has
also been noted to critically impact the health-related quality of
life (HRQoL) of patients through the clinical manifestations of
the disease and by socioeconomic, personal and environmental
factors.7 13 Pain and fatigue are other important features of RA
which are especially relevant from the patient perspective.8 14–16
In this study, we sought to quantify the impact of simultan-
eous achievement of clinical, functional and structural efﬁcacy
on work-related outcomes, HRQoL, pain and fatigue by
pooling data from three randomised clinical trials of adalimu-
mab for the treatment of RA among patients with both early-
stage and late-stage disease.
PATIENTS AND METHODS
Patients
Data were drawn from three separate randomised controlled
trials in RA: DE019 (NCT00195702), which enrolled patients
with experienced RA (disease duration of at least 3 years with
moderately to severely active RA despite a minimum of
3 months of treatment with methotrexate (MTX)); PREMIER
(NCT00195663), which enrolled MTX-naive patients with
early RA (disease duration <3 years) and OPTIMA
(NCT00420927), which enrolled patients with early RA and
included patients who failed to achieve stable low disease activ-
ity (LDA) (DAS28(CRP) <3.2 at weeks 22 and 26) with MTX.
The design and primary results of the DE019, PREMIER and
OPTIMA trials have been described elsewhere.17–20
A pooled intent-to-treat population included all patients from
these trials who were randomised and received at least one dose
of study drug. The present analysis includes all patients from
DE019 and PREMIER. Due to the rerandomisation in the
OPTIMA trial, only patients who failed to achieve LDA (DAS28
(CRP) <3.2) with MTX during Period 1 of OPTIMA were
included in the analysis. For these patients, the beginning of
Period 2 was considered the baseline period. Patients with
missing DAS28(CRP), HAQ-DI or change in modiﬁed total
Sharp score (ΔmTSS) at baseline or week 26 were excluded
from the present study.
The simultaneous achievement of stringent control of the
signs and symptoms of inﬂammation, normal physical function
and the absence of radiographic progression, herein referred as
comprehensive disease control (CDC), was evaluated at week
26. Stringent control of the signs and symptoms of inﬂamma-
tion was assessed by DAS28(CRP) and deﬁned as DAS28(CRP)
<2.6.2 6 21 Normal physical function was assessed using the
Disability Index of the HAQ-DI22 and deﬁned as HAQ-DI
<0.5.4 23 Radiographic progression was assessed using radio-
graphs of the hands/wrists and feet scored using the mTSS
method.24–26 Absence of radiographic progression was deﬁned
as a ≤0.5 unit change from baseline in mTSS.27 Patients who
achieved all three components were considered to have achieved
CDC (‘CDC achievers’), while patients who achieved either
none or any one or two (partial achievers) of the three compo-
nents were considered to have not achieved CDC (‘CDC
non-achievers’).
Outcomes
Work-related outcomes were measured in DE032, the economic
companion to PREMIER, and in OPTIMA. Work outcomes
were analysed in each trial separately because of different deﬁni-
tions across the trials. Work outcomes in PREMIER/DE032
were measured using the Patient Health Economic
Questionnaire (P-HEQ) and included the number of work days
missed and the level at which work performance has been
affected for employed patients with RA and homemakers separ-
ately. The level at which work performance has been affected
was measured using a Visual Analogue Scale (VAS) scale ranging
from 0 to 100.28 Work outcomes in OPTIMA were measured
using the Work Productivity and Activity Impairment (WPAI)
questionnaire29 and the RA-Work Instability Scale (RA-WIS).30
WPAI consists of six questions regarding the ability to work and
perform regular activities during the past 7 days. WPAI evaluates
absenteeism, presenteeism and work impairment among
employed patients and activity impairment among all patients.
RA-WIS is a 23-item questionnaire which quantiﬁes ‘the state in
which the consequences of a mismatch between an individual’s
functional abilities and the demands of his or her job can
threaten continuing employment if they are not resolved’.30
HRQoL was measured using the Short Form 36 (SF-36)
health survey. The SF-36 is a 36-item generic HRQoL measure
to assess the patient’s view of his or her health consisting of two
summary scales: physical (PCS) and mental component scores
(MCS). For each component, a normalised summary score was
calculated such that the average in the general population is 50
(with an SD of 10) using eight subdomains: Physical
Functioning, Role-Physical, Bodily Pain and General Health for
PCS, and Vitality, Social Functioning, Role-Emotional and
Mental Health for MCS. Scores range from 0 to 100, with
greater scores reﬂecting better health status.31–34 The minimal
clinically important difference (MCID) for the SF-36 PCS and
MCS is a 2.5-point increase from baseline.35 SF-36 information
was not collected in the OPTIMA trial.
Pain was measured using a VAS ranging from no pain to
worst pain imaginable, with a higher score indicating worse
pain. The MCID for VAS-Pain was a 10-mm decrease from base-
line.36 Fatigue was measured using the Functional Assessment of
Chronic Illness Therapy-Fatigue (FACIT-F), a symptom-speciﬁc
scale validated for patients with RA. The 13-item subscale is
self-administered using a 5-point Likert rating scale and ranges
between 0 and 52 with higher values indicating less fatigue.37
The MCID for FACIT-Fatigue is a 4-point increase from
baseline.32
Statistical analysis
Baseline characteristics were described for patients who achieved
and did not achieve CDC at week 26. The change from baseline
to week 26 for each outcome variable was compared between
CDC achievers and non-achievers using linear regression adjust-
ing for the baseline value of each outcome. Work outcomes
measured using the P-HEQ were analysed in PREMIER only,
while work outcomes measured using WPAI and RA-WIS were
analysed in OPTIMA only. Similar analyses were performed to
compare change from baseline to week 52. VAS-Pain and
FACIT-F were analysed by pooling data from all three rando-
mised clinical trials and in each trial separately. SF-36 PCS and
SF-36 PCS were analysed by pooling DE019 and PREMIER
because these HRQoL measures were not collected in OPTIMA.
Separate analyses were conducted within the early RA
(PREMIER), the MTX-failure (OPTIMA) and the experienced
RA (DE019) populations. To gauge the incremental beneﬁt of
the simultaneous achievement of the three CDC components,
the differences in SF-36 PCS, MCS, FACIT-F and VAS-Pain
were compared between patients achieving all three components
compared with achieving each component individually using a
full interaction model adjusting for the baseline value of each
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Table 1 Patient characteristics of week 26 CDC achievers and non-achievers
CDC achievers Non-achievers
N=200 N=1267
Demographics
Age, mean±SD 48.5±13.3 53.9±13.0
Female, n (%) 123 (61.5) 973 (76.8)
Trial, n (%)
OPTIMA 58 (29.0) 255 (20.1)
PREMIER 98 (49.0) 563 (44.4)
DE019 44 (22.0) 449 (35.4)
Study outcomes, mean±SD
Continuous CDC components
DAS28 5.2±1.3 5.8±1.1
HAQ-DI 0.9±0.6 1.5±0.6
mTSS 20.9±31.6 37.1±44.7
Patient-reported outcomes
SF-36 physical component score*,† 34.2±8.9 29.7±8.0
SF-36 mental component score*,† 48.2±12.4 45.9±12.0
VAS-Pain* 47.8±25.9 56.3±23.5
FACIT-Fatigue‡ 35.3±10.8 29.0±11.2
Lab values
Haemoglobin (g/dL) 13.1±1.5 12.8±1.5
Creatine (mg/dL) 0.8±0.2 0.7±0.2
Work-related outcomes in OPTIMA§
Absenteeism* 9.6±23.1 17.3±30.9
Presenteeism* 25.9±25.2 45.6±27.2
Activity impairment* 26.9±24.2 47.8±23.9
Work impairment* 29.4±26.5 49.9±30.9
Work instability scale 6.7±6.6 11.7±7.2
Work-related outcomes in PREMIER/DE032¶
Number of work days missed among employed patients in the last 4 weeks 3.2±6.1 5.2±8.6
Level work performance has been affected among employed patients in the last week* 45.6±32.6 53.5±32.0
Number of work days missed among homemakers in the last 4 weeks 4.7±8.3 7.2±10.1
Level work performance has been affected among homemakers in the last week* 43.6±26.8 62.4±26.4
Additional measures
Clinical characteristics, mean±SD
RA duration (years) 2.7±5.1 4.4±7.3
Swollen joint count (66) 16.1±8.0 19.8±9.8
Tender joint count (68) 21.1±10.2 29.0±13.7
C reactive protein (mg/L) 20.1±23.7 27.7±33.6
Physician’s global assessment of disease activity* 58.7±18.5 64.5±17.2
Patient’s global assessment of disease activity* 55.0±25.6 60.6±23.3
Radiographic findings, mean±SD
Erosion score 12.6±18.5 20.9±25.0
Joint space narrowing 8.3±14.3 16.3±21.4
Components of CDC achievement at week 26, n (%)
Full achievement 200 (100.0) 0 (0.0)
Achieved HAQ <0.5 and DAS <2.6 0 (0.0) 58 (4.6)
Achieved HAQ <0.5 and ΔmTSS ≤0.5 0 (0.0) 216 (17.0)
Achieved DAS <2.6 and ΔmTSS ≤0.5 0 (0.0) 89 (7.0)
Achieved HAQ <0.5 only 0 (0.0) 95 (7.5)
Achieved DAS <2.6 only 0 (0.0) 33 (2.6)
Achieved ΔmTSS ≤0.5 only 0 (0.0) 495 (39.1)
Achieved none 0 (0.0) 281 (22.2)
ACR-EULAR remission achievement at week 26, n (%)
Yes 65 (33.0) 29 (2.3)
*Measured from 0 to 100.
†Not measured in OPTIMA patients.
‡Measured from 0 to 52. Greater values indicate less fatigue.
§Among OPTIMA patients only.
¶Among PREMIER/DE032 patients only.
ACR-EULAR, American College of Rheumatology-European League Against Rheumatism; CDC, comprehensive disease control; DAS, Disease Activity Score; FACIT, Functional Assessment
of Chronic Illness Therapy; HAQ-DI, Health Assessment Questionnaire disability index; RA, rheumatoid arthritis; SF-36, Short Form 36; VAS, Visual Analogue Scale; mTSS, modified total
Sharp score; ΔmTSS, change in modified total Sharp score.
Clinical and epidemiological research
Emery P, et al. Ann Rheum Dis 2015;74:2165–2174. doi:10.1136/annrheumdis-2014-205302 2167
Table 2 Comparison of patient-reported and work-related outcomes by week 26 CDC achievement*†
Patient-reported outcomes in the pooled population
CDC achievers
(A)
Non-achievers
(B)
Difference
(C)=(A)–(B)
N=200 N=1267
Mean (95% CI) Mean (95% CI) Mean (95% CI) p Value
Week 26
VAS-Pain change, N=1463 −46.91 (−49.83 to −43.98) −26.88 (−28.04 to −25.72) −20.03 (−23.18 to −16.88)‡ <0.0001
n=200 n=1263
FACIT-Fatigue change, N=1452 13.29 (12.03 to 14.54) 7.51 (7.02 to 8.00) 5.78 (4.42 to 7.13)‡ <0.0001
n=196 n=1256
SF-36 mental change, N=1086§ 8.06 (6.45 to 9.66) 4.98 (4.39 to 5.57) 3.07 (1.36 to 4.78)‡ 0.0004
n=131 n=955
SF-36 physical change, N=1086§ 19.66 (18.13 to 21.19) 8.91 (8.35 to 9.47) 10.76 (9.12 to 12.39)‡ <0.0001
n=131 n=955
Week 52
VAS-Pain change, N=1306 −45.68 (−48.76 to −42.61) −28.83 (−30.08 to −27.57) −16.86 (−20.18 to −13.53)‡ <0.0001
n=189 n=1117
FACIT-Fatigue change, N=1326 12.98 (11.66 to 14.30) 8.05 (7.52 to 8.57) 4.93 (3.51 to 6.36)‡ <0.0001
n=186 n=1140
SF-36 mental change, N=1001§ 7.26 (5.61 to 8.92) 5.12 (4.49 to 5.74) 2.15 (0.38 to 3.91) 0.0174
n=126 n=875
SF-36 physical change, N=1001§ 19.37 (17.73 to 21.01) 10.03 (9.42 to 10.65) 9.34 (7.57 to 11.10)‡ <0.0001
n=126 n=875
Work-related outcomes in PREMIER/DE032¶
CDC achievers
(A)
Non-achievers
(B)
Difference
(C)=(A)−(B)
N=98 N=563
Mean (95% CI) Mean (95% CI) Mean (95% CI) p Value
Week 26
P-HEQ absenteeism among
employed patients, N=284
9.69 (3.36 to 16.02) 11.87 (8.82 to 14.93) −2.19 (−9.22 to 4.85) 0.5414
n=54 n=230
P-HEQ presenteeism among
employed patients, N=278
−44.23 (−50.30 to −38.17) −29.94 (−32.84 to −27.04) −14.30 (−21.03 to −7.56) <0.0001
n=52 n=226
P-HEQ absenteeism among
homemakers, N=182
2.30 (−5.88 to 10.48) 8.51 (5.32 to 11.69) −6.21 (−14.99 to 2.58) 0.1650
n=24 n=158
P-HEQ presenteeism among
homemakers, N=179
−52.00 (−61.89 to −42.11) −31.52 (−35.16 to −27.87) −20.49 (−31.07 to −9.90) 0.0002
n=22 n=157
Week 52
P-HEQ absenteeism among
employed patients, N=239
6.80 (−2.71 to 16.32) 14.03 (9.09 to 18.98) −7.23 (−17.96 to 3.51) 0.1860
n=51 n=188
P-HEQ presenteeism among
employed patients, N=237
−46.29 (−51.49 to −41.10) −33.65 (−36.33 to −30.97) −12.64 (−18.50 to −6.78) <0.0001
n=50 n=187
P-HEQ absenteeism among
homemakers, N=154
2.94 (−12.62 to 18.49) 12.97 (6.46 to 19.47) −10.03 (−26.90 to 6.84) 0.2420
n=23 n=131
P-HEQ presenteeism among
homemakers, N=152
−51.12 (−60.83 to −41.41) −34.16 (−38.09 to −30.24) −16.96 (−27.49 to −6.42) 0.0018
n=22 n=130
Work-related outcomes in OPTIMA**
CDC achievers
(A)
Non-achievers
(B)
Difference
(C)=(A)−(B)
N=58 N=255
Mean (95% CI) Mean (95% CI) Mean (95% CI) p Value
Week 26
WPAI activity impairment, N=308 −28.89 (−34.12 to −23.67) −10.94 (−13.37 to −8.51) −17.96 (−23.81 to −12.10) <0.0001
n=58 n=250
WPAI work impairment, N=131 −25.47 (−32.88 to −18.06) −7.77 (−12.30 to −3.24) −17.70 (−26.59 to −8.80) 0.0001
n=37 n=94
WPAI absenteeism, N=131 −8.20 (−14.42 to −1.99) −1.53 (−5.42 to 2.35) −6.67 (−14.02 to 0.68) 0.0750
n=37 n=94
WPAI presenteeism, N=144 −23.19 (−29.04 to −17.34) −9.41 (−12.99 to −5.82) −13.78 (−20.82 to −6.74) 0.0002
n=41 n=103
RA-WIS, N=153 −5.72 (−7.45 to −3.99) −2.09 (−3.00 to −1.18) −3.63 (−5.61 to −1.65) 0.0004
n=34 n=119
Continued
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outcome. To assess differences between CDC achievement and
ACR-EULAR remission achievement, the differences in SF-36
PCS, MCS, FACIT-F and VAS-Pain were compared between
patients achieving CDC compared with those achieving
ACR-EULAR remission (Boolean-based deﬁnition4) but not
CDC adjusting for the baseline value of each outcome.
RESULTS
A total of 1467 patients were included in the pooled trial
sample (493 (33.6%) from DE019, 661 (45.1%) from
PREMIER and 313 (21.3%) from OPTIMA) of whom 200
(13.6%) achieved CDC. Overall, patients who achieved CDC at
week 26 were younger, had lower mean DAS28(CRP),
HAQ-DI, mTSS and VAS-Pain, and higher mean FACIT-F, SF-36
PCS and SF-36 MCS scores (table 1).
Pooled RA population
After adjusting for the baseline value of the outcome, CDC at
week 26 was associated with the following improvements in
PROs at week 26: a 20.0 (95% CI 16.9 to 23.2) point improve-
ment in change from baseline in VAS-Pain; a 5.8 (4.4 to 7.1)
point improvement in FACIT-F; a 10.8 (9.1 to 12.4) point
improvement in SF-36 PCS and a 3.1 (1.4 to 4.8) point
improvement in SF-36 MCS. Further, after adjusting for the
baseline value of the outcome, CDC at week 26 was associated
with the following improvements in PROs at week 52: a 16.9
(13.5–20.2) point improvement in VAS-Pain; a 4.9 (3.5–6.4)
point improvement in FACIT-F; a 9.3 (7.6–11.1) point improve-
ment in SF-36 PCS and a 2.2 (0.4–3.9) point improvement in
SF-36 MCS (table 2). All improvements were statistically signiﬁ-
cant. In addition, the differences in SF-36 PCS, VAS-Pain and
FACIT-F exceeded their respective MCIDs at both week 26 and
52. The difference in SF-36 MCS only exceeded the MCID at
week 26.
Early RA population
Among patients with early RA enrolled in PREMIER, CDC
achievement was associated with statistically signiﬁcant improve-
ments in P-HEQ presenteeism at weeks 26 and 52 (table 2).
Achievement of CDC at week 26 was also associated with statis-
tically signiﬁcant and clinically meaningful differences in SF-36
PCS, VAS-Pain and FACIT-F at both week 26 and 52 and statis-
tically signiﬁcant and clinically meaningful differences in SF-36
MCS at week 26 (ﬁgures 1 and 2).
Early RA MTX-failure population
Among all patients with early RA enrolled in OPTIMA who
failed to achieve LDA with MTX, achievement of CDC at week
26 was associated with statistically signiﬁcant improvements in
change in WPAI activity impairment, WPAI work impairment,
WPAI presenteeism and RA-WIS at weeks 26 and 52 after
adjusting for baseline values (table 2). Among all MTX-failure
patients, achievement of CDC at week 26 was associated with
statistically signiﬁcant differences in VAS-Pain and FACIT-F at
weeks 26 and 52 after adjusting for baseline values. The differ-
ences in VAS-Pain exceeded the MCID at both week 26 and 52
(ﬁgures 1 and 2).
Established RA population
Among patients with established RA enrolled in DE019,
achievement of CDC at week 26 was associated with statistically
signiﬁcant improvements in change in SF-36 PCS, FACIT-F and
VAS-Pain at weeks 26 and 52 after adjusting for the baseline
scores (ﬁgures 1 and 2).
Incremental value of CDC
Compared with patients achieving DAS remission alone, CDC
achievement was associated with statistically signiﬁcant and clin-
ically meaningful differences of 7.0 (4.0–10.0) and 6.9 (3.5–
10.4) in SF-36 PCS at weeks 26 and 52, respectively. CDC
Table 2 Continued
Work-related outcomes in OPTIMA**
CDC achievers
(A)
Non-achievers
(B)
Difference
(C)=(A)−(B)
N=58 N=255
Mean (95% CI) Mean (95% CI) Mean (95% CI) p Value
Week 52
WPAI activity impairment, N=284 −29.85 (−35.69 to −24.01) −10.60 (−13.37 to −7.84) −19.24 (−25.81 to −12.68) <0.0001
n=55 n=229
WPAI work impairment, N=125 −26.09 (−32.86 to −19.33) −11.63 (−16.00 to −7.27) −14.46 (−22.72 to −6.20) 0.0007
n=38 n=87
WPAI absenteeism, N=125 −8.93 (−14.10 to −3.76) −4.56 (−7.96 to −1.15) −4.37 (−10.59 to 1.84) 0.1659
n=38 n=87
WPAI presenteeism, N=134 −24.31 (−30.07 to −18.56) −9.81 (−13.39 to −6.23) −14.50 (−21.48 to −7.53) 0.0001
n=39 n=95
RA-WIS, N=146 −6.38 (−8.40 to −4.36) −1.74 (−2.81 to −0.67) −4.64 (−6.96 to −2.32) 0.0001
n=33 n=113
Boldface indicates statistical significance at the 0.05 level.
*The adjusted analysis compared the mean change from baseline for each outcome by CDC achievement using an analysis of covariance model in which the impact of CDC on change
in the outcome was estimated adjusting for the baseline value of the outcome.
†For VAS-Pain, negative change from baseline indicates an improvement in the outcome. For FACIT-Fatigue, SF-36 Mental Health and SF-36 Physical Health, positive change from
baseline indicates an improvement in the outcome.
‡Indicates difference exceeds the respective MCID for the outcome.
§SF-36 Physical and Mental Health Component Scores were not measured in OPTIMA.
¶For P-HEQ absenteeism, the mean cumulative number of work days missed from baseline to week 26 and from baseline to week 52 was compared by CDC achievement. For P-HEQ
presenteeism, the mean change from baseline to week 26 and from baseline to week 52 was compared by CDC achievement adjusting for the baseline P-HEQ presenteeism.
**For WPAI measures and RA-WIS, the mean change from baseline to week 26 and from baseline to week 52 was compared by CDC achievement adjusting for the baseline value.
CDC, comprehensive disease control; FACIT, Functional Assessment of Chronic Illness Therapy; MCID, minimal clinically important difference; P-HEQ, Patient Health Economic
Questionnaire; RA-WIS, Rheumatoid Arthritis-Work Instability Scale; SF-36, Short Form 36; VAS, Visual Analogue Scale; WPAI, Work Productivity and Activity Impairment.
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achievement was also associated with a 9.0 (1.6–16.3) point
decrease in VAS-Pain compared with DAS remission alone.
When compared with patients achieving normal physical func-
tion alone, CDC achievement was associated with statistically
signiﬁcant differences of 4.0 (2.0–6.0) and 2.9 (0.6–5.2) in
SF-36 PCS and 7.6 (3.1–12.1) and 5.5 (0.5–10.6) reductions in
VAS-Pain at weeks 26 and 52, respectively. CDC achievement
was associated with statistically signiﬁcant and clinically mean-
ingful improvements in SF-36 PCS, MCS, FACIT-F and
VAS-Pain at both week 26 and 52 compared with patients with
the absence of radiographic progression alone (table 3).
Comparison with ACR-EULAR remission
There were no statistically signiﬁcant differences in VAS-Pain,
FACIT-Fatigue, SF-36 PCS and SF-36 MCS between patients
achieving CDC and patients achieving ACR-EULAR remission
but not CDC at weeks 26 and 52 (table 4).
DISCUSSION
Clinical, functional and structural efﬁcacy outcomes are the
three aspects against which therapies are evaluated in the
disease management for RA. In additional, simultaneous
achievement of all three is proposed as the long-term treatment
Figure 1 Comparison of patient-reported outcomes by CDC achievement and trial population at week 26.1 FACIT, Functional Assessment of
Chronic Illness Therapy; SF-36, Short Form 36; VAS, Visual Analogue Scale; RA, rheumatoid arthritis; MCS, mental component score; PCS, physical
component score; CDC, comprehensive disease control; MTX, methotrexate.
Figure 2 Comparison of patient-reported outcomes by CDC achievement and trial population at week 52.1 FACIT, Functional Assessment of
Chronic Illness Therapy; SF-36, Short Form 36; VAS, Visual Analogue Scale; RA, rheumatoid arthritis; MCS, mental component score; PCS, physical
component score; CDC, comprehensive disease control; MTX, methotrexate.
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Table 3 Change in patient-reported outcomes from baseline to week 26 and week 52 by week 26 CDC components achieved (DE019, PREMIER and OPTIMA)
Continuous
outcomes*†
CDC achievers (A)
Achieved DAS
remission
(B)
Achieved normal physician
function
(C)
Achieved non-radiographic
progression
(D)
Difference
(E)=(A)−(B)
Difference
(F)=(A)−(C)
Difference
(G)=(A)−(D)
N=200 N=380 N=569 N=1000
Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI)
Week 26
VAS-Pain
change, N=1463
−47.49 (−50.07 to −44.91) −42.21 (−48.53 to −35.90) −39.89 (−43.62 to −36.16) −18.32 (−19.95 to −16.68) −5.27 (−12.09 to 1.55) −7.60 (−12.11 to −3.08) −29.17 (−32.24 to −26.11)
200 378 568 997
FACIT-Fatigue
change, N=1452
13.65 (12.49 to 14.81) 10.81 (8.02 to 13.60) 13.92 (12.27 to 15.56) 4.42 (3.70 to 5.15) 2.84 (−0.18 to 5.86) −0.27 (−2.27 to 1.74) 9.23 (7.84 to 10.61)
196 373 563 988
SF-36 mental
change, N=1086
8.08 (6.50 to 9.67) 8.96 (5.55 to 12.38) 7.97 (5.94 to 9.99) 3.54 (2.56 to 4.52) −0.88 (−4.64 to 2.89) 0.12 (−2.45 to 2.68) 4.54 (2.68 to 6.41)
131 246 420 680
SF-36 physical
change, N=1086
20.36 (19.09 to 21.62) 13.39 (10.70 to 16.08) 16.33 (14.73 to 17.93) 4.81 (4.04 to 5.59) 6.97 (3.99 to 9.95) 4.03 (2.01 to 6.05) 15.55 (14.05 to 17.04)
131 246 420 680
Week 52
VAS-Pain
change, N=1306
−46.11 (−48.95 to −43.27) −37.16 (−43.92 to −30.40) −40.61 (−44.80 to −36.42) −21.02 (−22.87 to −19.17) −8.95 (−16.28 to −1.62) −5.50 (−10.55 to −0.45) −25.09 (−28.49 to −21.68)
189 350 516 900
FACIT-Fatigue
change, N=1326
13.27 (12.01 to 14.52) 10.35 (7.43 to 13.27) 13.61 (11.82 to 15.40) 5.42 (4.63 to 6.22) 2.92 (−0.26 to 6.09) −0.35 (−2.52 to 1.83) 7.84 (6.34 to 9.34)
186 348 521 912
SF-36 mental
change, N=1001
7.28 (5.64 to 8.92) 8.52 (4.91 to 12.13) 6.93 (4.80 to 9.06) 3.95 (2.92 to 4.99) −1.24 (−5.21 to 2.73) 0.35 (−2.34 to 3.04) 3.33 (1.38 to 5.27)
126 236 393 630
SF-36 physical
change, N=1001
20.01 (18.57 to 21.45) 13.07 (9.96 to 16.18) 17.12 (15.29 to 18.96) 6.42 (5.52 to 7.31) 6.94 (3.51 to 10.37) 2.89 (0.57 to 5.20) 13.59 (11.88 to 15.30)
126 236 393 630
Boldface indicates statistical significance at the 0.05 level.
*The adjusted analysis compared the mean change from baseline for each outcome by CDC component achievement using an analysis of covariance model in which the impact of component achievement on change in the outcome was estimated
adjusting for the baseline value of the outcome.
†For VAS-Pain, negative change from baseline indicates an improvement in the outcome. For FACIT-Fatigue, SF-36 Mental Health and SF-36 Physical Health, positive change from baseline indicates an improvement in the outcome.
CDC, comprehensive disease control; DAS, Disease Activity Score; FACIT, Functional Assessment of Chronic Illness Therapy; SF-36, Short Form 36; VAS, Visual Analogue Scale.
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goal with implied beneﬁts on patients. While correlated,
these three aspects have respective variations and each of
them adds value while being achieved simultaneously. The
purpose of this study is to assess the impact of such achieve-
ment, referred to as CDC, on short-term as well as long-term
patient outcomes including fatigue, pain, work outcomes and
general physical and mental health. CDC includes DAS remis-
sion of <2.6, normal physical function (as measured by
HAQ-DI) and absence of radiographic progression (as measured
by mTSS).
In the present study, CDC was associated with signiﬁcant
improvements in patient’s work-related outcomes, HRQoL,
pain and fatigue. These improvements were observed both at
the time of CDC achievement and 26 weeks later. The improve-
ments in HRQoL are especially pronounced, as patients who
achieve CDC are 2.5 times more likely to have SF-36 MCS
score greater than the general population norm and 9.8 times
more likely to have SF-36 PCS greater than the general popula-
tion norm at week 26. Similarly, CDC achievers are 2.3 times
more likely to have SF-36 MCS score greater than the general
population norm and 6.7 times more likely to have SF-36 PCS
greater than the general population norm at week 52. These
improvements are associated with reduced healthcare use and
costs and reduced mortality,38 39 further demonstrating that
CDC achievement is associated with broad and signiﬁcant
improvements in patient outcomes. Also, the differences
between the CDC achievers and non-achievers for all the mea-
sured outcomes were greater than the clinically meaningful
thresholds for each of the outcome. The simultaneous achieve-
ment of all three CDC domains was also demonstrated to be
associated with signiﬁcant improvements in physical function
and pain compared with achieving the individual domains in
isolation. This result suggests there may be an incremental
beneﬁt related to achieving all three components. An adjusted
correlation analysis of the individual components showed that
nearly 50%–55% of the variations in the outcomes at week 26
(SF-36 and VAS-Pain) were explained by improvements in
DAS28 remission, 35%–47% by improvements in HAQ-DI
score and 2%–9% by mTSS scores.
Current recommendations state that treatment of RA should
focus on achieving clinical remission to inhibit progression of
joint damage and improve physical function and quality of life.3
The ACR and EULAR also recognise the importance of remis-
sion for predicting improvement in physical function and
halting radiographic progression. It is noted in the EULAR
2013 recommendation update that ACR-EULAR remission
should serve as the optimal treatment target to be used in
routine clinical practice, while LDA is a good alternative for the
many patients who cannot attain remission. Within the pooled
population in this study, a total of 94 patients experienced
ACR-EULAR remission, of whom 65 (69.1%) also achieved
CDC. The presence of radiographic progression was the most
common reason for discordance (17 patients). There were no
signiﬁcant differences in SF-36 PCS, MCS, FACIT-F or
VAS-Pain between patients achieving CDC and those achieving
ACR-EULAR remission (but not CDC), although this analysis
was limited by small sample size (table 4). Regardless of which
treatment target is selected, the long-term goal remains to maxi-
mise long-term HRQoL through control of symptoms, preven-
tion of structural damage, normalisation of function and social
participation. Discussions around the simultaneous achievement
of clinical, physical and structural efﬁcacy can also engage
Table 4 Change in patient-reported outcomes from baseline to week 26 and week 52 by week 26 CDC/ACR-EULAR remission achievement
(DE019, PREMIER and OPTIMA)
CDC achievers (A)
ACR-EULAR remission
but not CDC
(B)
Neither ACR-EULAR
remission nor CDC
(C)
Difference
(D)=(A)−(B)
N=200 N=29 N=1226
Continuous outcomes*† Mean (95% CI) Mean (95% CI) Mean (95% CI) Mean (95% CI) p Value
Week 26
VAS-Pain change, N=1451 −47.07 (−49.96 to −44.19) −51.59 (−59.12 to −44.05) −26.45 (−27.61 to −25.29) 4.51 (−3.55 to 12.57) 0.2722
200 29 1222
FACIT-Fatigue change, N=1440 13.31 (12.06 to 14.56) 12.82 (9.62 to 16.01) 7.42 (6.92 to 7.91) 0.50 (−2.93 to 3.92) 0.7764
196 29 1215
SF-36 mental change, N=1085 8.06 (6.46 to 9.67) 6.05 (2.52 to 9.57) 4.95 (4.35 to 5.55) 2.02 (−1.85 to 5.89) 0.3065
131 27 927
SF-36 physical change, N=1085 19.69 (18.19 to 21.20) 19.17 (15.91 to 22.44) 8.59 (8.03 to 9.15) 0.52 (−3.07 to 4.11) 0.7754
131 27 927
Week 52
VAS-Pain change, N=1294 −45.84 (−48.87 to −42.80) −51.22 (−59.36 to −43.09) −28.52 (−29.79 to −27.26) 5.39 (−3.29 to 14.07) 0.2234
189 26 1079
FACIT-Fatigue change, N=1314 13.00 (11.69 to 14.31) 14.16 (10.64 to 17.68) 7.97 (7.44 to 8.50) −1.16 (−4.90 to 2.59) 0.5441
186 25 1103
SF-36 mental change, N=1000 7.27 (5.62 to 8.93) 8.19 (4.48 to 11.89) 5.03 (4.39 to 5.66) −0.91 (−4.97 to 3.14) 0.6580
126 25 849
SF-36 physical change, N=1000 19.38 (17.77 to 21.00) 20.54 (16.97 to 24.11) 9.72 (9.11 to 10.34) −1.16 (−5.08 to 2.76) 0.5626
126 25 849
*The adjusted analysis compared the mean change from baseline for each outcome by CDC/ACR-EULAR achievement using an analysis of covariance model in which the impact of
achievement on change in the outcome was estimated adjusting for the baseline value of the outcome.
†For VAS-Pain, negative change from baseline indicates an improvement in the outcome. For FACIT-Fatigue, SF-36 Mental Health and SF-36 Physical Health, positive change from
baseline indicates an improvement in the outcome.
ACR-EULAR, American College of Rheumatology-European League Against Rheumatism; CDC, comprehensive disease control; FACIT, Functional Assessment of Chronic Illness Therapy;
SF-36, Short Form 36; VAS, Visual Analogue Scale.
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patients and encourage patients to involve their observation
around physical function.
This analysis has several strengths. First, we pooled data from
three large RCTs of early RA, established RA and MTX non-
responders and found that within trial, analyses were consistent
with the results from the pooled data. So while patients with
experienced disease may achieve CDC at a lower rate, there is
no differential impact of CDC achievement on quality of life by
RA duration. Further, improvements in PROs observed at
52 weeks were similar to those observed at 26 weeks, demon-
strating that achievement of CDC may have a long-standing
effect on quality of life.
This analysis has limitations. First, patient characteristics were
not balanced between CDC achievers and non-achievers.
However, adjustment for these factors may not account for all
baseline differences between CDC achievers and non-achievers.
An observed case analysis was performed, which led to 17% of
patients being dropped from the analysis. However, imputation
procedures require assumptions about the underlying missing
data mechanism and may not be appropriate for this analysis.
Last, not all outcomes, such as SF-36, were measured in all trials
making it difﬁcult to assess the full impact of CDC achievement
on SF-36 in patients who were non-responders to MTX.
This post hoc analysis of three individual clinical trials
demonstrated the beneﬁts of CDC at the time of achievement
and 6 months postachievement. This ﬁnding can be strength-
ened if supported by the results of a future prospective rando-
mised controlled trial using CDC as a ranked secondary
endpoint. Future research into whether the beneﬁts of CDC are
maintained over a longer-term is also warranted.
CDC achievement was associated with clinically meaningful
improvements in work-related outcomes, HRQoL, pain and
fatigue compared with those who did not achieve CDC. These
results demonstrate that simultaneous improvement in all three
RA domains can provide meaningful beneﬁts to patients.
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